Insights into therapy: tryptophan oxidation and HIV infection.
New data from Favre and colleagues strengthen the link between activation of the tryptophan oxidation (TOx) pathway--via the indoleamine 2,3-dioxygenase enzymes IDO1 and IDO2--and chronic inflammation in progressive HIV disease. It can now be appreciated that a pathogenic TOx activation cycle exists in HIV. TOx regulation is a therapeutic target for other diseases, such as cancer and autoimmune disorders. Here TOx control is examined with an eye to eventual therapeutic intervention in HIV disease.
Murray
Michael F
MF
Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA. mmurray@partners.org
D015095:3-Hydroxyanthranilic Acid / Q000378:metabolism; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000201:enzymology / Q000276:immunology / Q000821:virology; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015658:HIV Infections / Q000201:enzymology / Q000276:immunology / Q000628:therapy* / Q000821:virology; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D007249:Inflammation / Q000201:enzymology / Q000276:immunology / Q000628:therapy* / Q000821:virology; D018836:Inflammation Mediators / Q000276:immunology; D020381:Interleukin-17 / Q000276:immunology; D007737:Kynurenine / Q000378:metabolism; D010084:Oxidation-Reduction; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology / Q000378:metabolism / Q000821:virology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism / Q000821:virology; D014364:Tryptophan / Q000378:metabolism*; D019562:Viral Load
D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D018836:Inflammation Mediators; D020381:Interleukin-17; D015095:3-Hydroxyanthranilic Acid; D007737:Kynurenine; D014364:Tryptophan